Trials / Unknown

UnknownNCT05278195

Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers

Assessing the Prognosis of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Hepatocellular Carcinoma by Using Clinical and Imaging Biomarkers

Status: Unknown
Phase: —
Study type: Observational
Enrollment: 300 (estimated)

Sponsor: Zhongda Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to id transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular targeted therapies in patients with hepatocellular carcinoma (HCC) .

Conditions

Hepatocellular Carcinoma

Timeline

Start date: 2022-04-01
Primary completion: 2022-12-01
Completion: 2023-12-01
First posted: 2022-03-14
Last updated: 2022-03-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05278195. Inclusion in this directory is not an endorsement.